Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
about
Treatment of Metastatic Colorectal Cancer: Standard of Care and Future PerspectivesNew findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR responseDrug rechallenge and treatment beyond progression--implications for drug resistance.Palliative oxaliplatin-based chemotherapy after exposure to oxaliplatin in the adjuvant setting for colon cancerRechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer.Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients.Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy.Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer.The role of targeted therapy for gastrointestinal tumors.Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario.Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.Case histories in unresectable liver-dominant metastatic colorectal cancer.Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer.Emerging drugs in refractory colorectal cancer.Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational StudyClinical Application of Liquid Biopsy in Targeted Therapy of Metastatic Colorectal Cancer.Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck.A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS wild-type tumors who progressed after standard dose of cetuximab plus irinotecan.Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer.Colorectal cancer: Overcoming resistance to anti-EGFR therapy - where do we stand?Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting.Retreatment with Vismodegib after Progression in Advanced Basal Cell Carcinoma: First-Time Report of a Single-Institution Experience.Significance of Liquid Biopsy for Monitoring and Therapy Decision of Colorectal Cancer.Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review.Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review.Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients.How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer?Panitumumab rechallenge in chemorefractory patients with metastatic colorectal cancer.Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer.
P2860
Q26738801-9DD2D1F2-39AE-4662-9E22-291B404F7EA6Q26796348-18277883-6C42-40F2-A9B6-E881F94AEFDCQ35218647-1461FBC3-923D-44EB-B5B5-1012E18AD932Q35810693-23D3D80B-F5A0-4C20-ABFB-E9D20BD8940DQ35967416-90782E3E-F52F-45BD-A180-AF004E0A6DD0Q36062629-F337A4EE-86E8-40AE-97CF-E18B23696C95Q36280348-5A59A42F-C34E-4959-AEA0-D7FB5858999AQ36444723-7D9697C7-B63C-4072-ADF5-E7DD4CFFB02CQ37408810-42C34DF8-652B-474A-8720-FCA938C601AEQ37548830-6D1B6DDB-91E1-45F2-AF01-2E13F25200D6Q38163598-4EAD25EB-0882-474F-9E1B-45B3792F77D9Q38222585-BCC4FFCE-9C9B-4F58-A61A-2FD3C95A5797Q38253815-9DEF672D-A967-4604-86CA-6E64310EF826Q38265382-4EA11737-91B8-4EB7-9755-992925DAC62EQ38283664-7D18AC05-8F48-4415-8AA9-97AB66F7A6C0Q38516244-2CC47F3C-A31A-413A-B612-158BD079D261Q38570584-38D88404-4C31-4DED-9666-87576E227382Q39054543-E71FCDE7-218F-455E-A1DF-C163B3730F60Q40046547-64F38B7E-40FA-4BD6-9A8B-967B3007C50FQ42324056-B0C41676-8492-42AB-AEC7-05F652EDF314Q43130011-B0359C38-264C-47F1-A822-4FC92FDF959FQ43917817-5B404EDD-A1B5-44D2-AC9C-E85410DF30C5Q45376093-9469DB2A-9B52-4907-90A9-C2A550D0483DQ45975984-45DDC263-EA6C-46ED-98B2-93034CE36FB4Q46050091-F4FD19AB-D8B8-4EAF-A73F-31C336CD9EE8Q48000427-DB8616DB-E3D5-449E-8C23-D0F95F8A1823Q48128508-7CE24CC0-DC0B-4E41-A815-965B4A81FDE8Q48503747-81B480EC-C967-489F-BC75-D8E19332B24DQ48585692-DC99165E-CC99-443A-83BA-BF5456F2FFCEQ49922743-A07DEDB9-3775-4756-A2C4-7BD3D866ED6FQ50201433-6645C954-EC00-4399-894B-7D41B130DD21Q51099296-09B0846A-4D71-4E91-8805-2CDFCF298609Q53129943-93525484-E14B-4229-8CF5-2DBD4F88FA10Q55342871-108480A6-11DB-4C65-86A0-2F19E84DA9BD
P2860
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Cetuximab rechallenge in metas ...... away from acquired resistance?
@en
type
label
Cetuximab rechallenge in metas ...... away from acquired resistance?
@en
prefLabel
Cetuximab rechallenge in metas ...... away from acquired resistance?
@en
P2093
P50
P356
P1433
P1476
Cetuximab rechallenge in metas ...... away from acquired resistance?
@en
P2093
A M Frezza
P304
P356
10.1093/ANNONC/MDR623
P577
2012-03-05T00:00:00Z